此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

表达 CAR 的活化 T 淋巴细胞,异基因 HSCT 后复发的 CD19+ 恶性肿瘤(CARPASCIO) (CARPASCIO)

2026年9月30日 更新者:Helen Heslop、Baylor College of Medicine

表达嵌合抗原受体的活化 T 淋巴细胞用于治疗复发性 CD19 阳性恶性肿瘤的 I 期研究,异基因造血干细胞移植仅在植入后输注 (CARPASCIO)

Patients have a type of lymph gland cancer called Non-Hodgkin Lymphoma (NHL), acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL) (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment (including the best treatment known for these cancers). Because there is no standard treatment for this cancer at this time, subjects are asked to volunteer to be in a gene transfer research study using special immune cells.

The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research study combines two different ways of fighting disease, antibodies and T cells, hoping that they will work together. Both antibodies and T cells have been used to treat patients with cancers; they have shown promise, but have not been strong enough to cure most patients.

T cells can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person.

The antibody used in this study is called anti-CD19. This antibody sticks to cancer cells because of a substance on the outside of these cells called CD19. CD19 antibodies have been used to treat people with lymphoma and leukemia. For this study, the CD19 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. The T lymphocytes will also contain CD28, which stimulates T cells and makes them last longer.

Treatment with CD19/CD28 chimeric receptor-T cells has had activity against lymphoma and leukemia when the cells are made from the patients affected by these diseases. In this study, investigators are going to see if this treatment works even better when they make these cells from a healthy stem cell donor. If investigators are not able to collect blood from the stem cell donor, they will collect blood from the subject to make the CD19/CD28 chimeric receptor-T cells.

These CD19/CD28 chimeric receptor T cells are investigational products not approved by the FDA.

The purpose of this study is to find the biggest dose of chimeric T Cells that is safe, to see how long T cells with this chimeric receptor last, to learn what the side effects are, and to see whether this therapy might help people with lymphoma or leukemia after a stem cell transplantation from a donor.

研究概览

详细说明

The subject or his/her donor will give blood to make CD19/CD28 chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the T cells, the donor/subject's blood will be stimulated with growth factors to make the T cells grow. To get the CD19 antibody with CD28 to attach to the surface of the T cell, an antibody gene will be inserted into the T cell. This is done with a virus called a retrovirus that has been made for this study and will carry the antibody gene into the T cell. This virus also helps investigators find the T cells in the blood using a special laboratory test. Subjects will be followed for a total of 15 years to see if there are any long term side effects of gene transfer.

When a subject enrolls on this study, s/he will be assigned a dose of CD19/CD28 chimeric receptor-T cells and should not receive other cancer treatment until 6 weeks after cell infusion.

Several studies suggest that the infused T cells need room to be able to proliferate and accomplish their functions and that this may not happen if there are too many other T cells in circulation. Because of that, if the subject's level of circulating T cells is relatively high, s/hemay receive treatment with cyclophosphamide (Cytoxan) and fludarabine (chemotherapy drugs) before the T cells. If the subject is already receiving chemotherapy, this may not be needed.

The subject will be given an injection of cells into the vein through an IV at the assigned dose. The injection will take up to 10 minutes. The research staff will follow the subject in the clinic after the injection for up to 4 hours. If after a 4-6 week evaluation period after the infusion, the subject seems to be experiencing a benefit (confirmed by radiological studies, physical exam and/or symptoms), s/he may be able to receive up to 5 additional doses of the T cells. These additional infusions would be at least 4-6 weeks apart and at the same dose level received the first time or a lower dose.

There will be medical tests during and after treatment. To learn more about the way the CD19 chimeric receptor-T cells are working and how long they last in the body, extra blood will be drawn.

研究类型

介入性

注册 (实际的)

7

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • Texas Children's Hospital
      • Houston、Texas、美国、77030
        • Houston Methodist Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

PROCUREMENT

  • Group A: CD19+ B-ALL undergoing allogeneic HSCT or Group B: CD19+ B cell CLL or NHL undergoing allogeneic HSCT
  • Life expectancy of ≥12 weeks.
  • Patient has an appropriate donor identified for hematopoietic stem cell transplantation

TREATMENT

  • Any patient regardless of sex or age with CD19+ B-ALL undergoing allogeneic HSCT (Group A) OR any patient regardless of sex or age with CD19+ B-CLL or NHL undergoing allogeneic HSCT (Group B)

  • Residual disease at the time of transplant (bulky or minimal) or post transplant relapse as evidenced by PCR positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood. MRD will be defined as detection in blood or marrow of any of the following:

    • Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient's leukemia cells pre transplant on a post transplant evaluation.
    • An immune globulin rearrangement known to be a disease marker for this patient post transplant.
    • A leukemia specific phenotype post transplant at a level of ≥ 0.01%
    • Mixed donor chimerism (any level)
  • Life expectancy ≥ 6 weeks

  • Karnofsky/Lansky score ≥ 50%.

  • Bilirubin ≤ 2 times the upper limit of normal.

  • AST ≤ 3 times the upper limit of normal.

  • Estimated GFR > 50 mL/min

  • Hgb ≥ 7.0 (can be a transfused value)

  • Pulse oximetry of > 90% on room air

  • Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after ATL infusion. The male partner should use a condom.

  • Available allogeneic activated peripheral blood T cell products with >=15% expression of CD19.CAR-CD28ζ determined by flow cytometry (cell dose is based on total cell numbers and not individual antileukemic cell numbers).

  • No other investigational antitumor therapy for one month prior to entry in this study.

  • Patients or legal guardians must sign an informed consent.

Exclusion Criteria:

  • Severe intercurrent infection.
  • Evidence of GVHD > grade II.
  • Pregnant or lactating.
  • History of hypersensitivity reactions to murine protein-containing products.
  • Currently taking corticosteroids (>0.5 mg/kg/day prednisone or equivalent) for therapy of GVHD.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Subgroup A1

Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1

Patients will receive one of the following dose levels:

Dose Level 1: 5 ×10^5 cells/kg

Dose Level 2: 1×10^6 cells/kg

Dose Level 3: 5×10^6 cells/kg

实验性的:Subgroup B1

Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1

Patients will receive one of the following dose levels:

Dose Level 1: 5 ×10^5 cells/kg

Dose Level 2: 1×10^6 cells/kg

Dose Level 3: 5×10^6 cells/kg

实验性的:Subgroup A2

Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2

Patients will receive one of the following doses:

Dose Level one: 1x10^5 cells/kg

Dose Level 2: 5x10^5 cells/kg

Dose Level 3: 1x10^6 cells/kg

实验性的:Subgroup B2

Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2

Patients will receive one of the following doses:

Dose Level one: 1x10^5 cells/kg

Dose Level 2: 5x10^5 cells/kg

Dose Level 3: 1x10^6 cells/kg

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of patients with dose limiting toxicity
大体时间:6 weeks

Toxicity is evaluated using CTCAE, version 4.0. Dose limiting toxicity (DLT) will be defined as any of the following that is NOT (1) pre-existing, or (2) due to infection (to which patients with CLL and NHL are predisposed), or (3) due to underlying malignancy, and that may, after consultation with the FDA when indicated, be considered possibly, probably, or definitely related to the study cellular products:

  • Development of Grade III-IV GVHD or Grade II GVHD unresponsive to front line treatment;
  • Non-hematologic DLT is any grade 3 or grade 4 non-hematologic toxicity, including allergic reactions to T cell infusions.
  • Hematologic DLT is defined as any grade 4 hematologic toxicity, including secondary graft failure (as defined per protocol).
  • Patients with evidence of bone marrow disease (metastases or diffuse infiltration) are not evaluable for hematologic dose limiting toxicity.
6 weeks

次要结果测量

结果测量
措施说明
大体时间
Number of patients with tumor response
大体时间:8 weeks

We will summarize tumor response by overall response rates. Tumor burden will be measured before and after T cell therapy.

8 weeks
Frequency of T cell products
大体时间:Up to 15 years

The frequency of T cells transduced with the vector (T cells expressing CD19.CAR-CD28z) will be summarized at pre and post-infusion time points. Plots of growth curves will be generated to graphically illustrate patterns of T-cell expansion.

Up to 15 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Helen E Heslop, MD、Baylor College of Medicine

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年4月1日

初级完成 (实际的)

2019年10月1日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2014年1月29日

首先提交符合 QC 标准的

2014年1月29日

首次发布 (估计的)

2014年1月30日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅